NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer
This activity will help clinicians identify the best treatment options for their patients with bladder cancer.
Unraveling Cancer Pain Dynamics (UColorado)

The goal of this initiative is to provide education to clinicians, involved in the assessment and management of cancer pain in adult patients, on the appropriate and safe use of opioid analgesics, optimizing non-opioid analgesics and adjuvant medications, and integrating non-pharmacological appro

Unraveling Cancer Pain Dynamics (Yale)

The goal of this initiative is to provide education to clinicians, involved in the assessment and management of cancer pain in adult patients, on the appropriate and safe use of opioid analgesics, optimizing non-opioid analgesics and adjuvant medications, and integrating non-pharmacological appro

NCCN Tumor Boards: Multidisciplinary Management of Head and Neck Cancers
Despite advances in radiation therapy (RT) techniques for the treatment of head and neck cancers, patients with head and neck cancers continue to be at risk of oral and dental complications after surgery or RT because of treatment-induced xerostomia and salivary gland dysfunction, which are associated with increased dental caries.
NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer
This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.
NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer
It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.
NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
NCCN Pharmacy Updates: Updates in the Treatment of Kidney Cancer
The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.
NCCN Tumor Boards: The Role of Molecular Profiling in the Management of Uterine Cancer
Determining treatment regimens for patients with uterine cancer can be challenging. With the availability of increasingly advanced imaging, surgical, and radiation therapy techniques as well as novel systemic therapy options, evidence-based guidance is needed to inform and optimize treatment decisions.
NCCN Pharmacy Updates: What Grade Are You In? The Role of Targeted Therapy in Pediatric Diffuse High-Grade Gliomas
Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.

Pages

Subscribe to RSS - Live Webinar